Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats

References

• Bautista AM, Tan MA, Apostol JM. 2017. Lipid-lowering property of Clausena anisum-olens in hypercholesterolemic rats. Pharm Biol. 55:833–836.
   PubMed Web of Science ®Google Scholar
• Chung SY, Cheng FC, Lee MS, Lin JY, Lin MC, Wang MF. 2006. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. Am J Chin Med. 34:803–817.
   PubMed Web of Science ®Google Scholar
• Cruz-Correa OF, Leon-Cachon RB, Barrera-Saldana HA, Soberon X. 2017. Prediction of atorvastatin plasmatic concentrations in healthy volunteers using integrated pharmacogenetics sequencing. Pharmacogenomics. 18:121–131.
   PubMed Web of Science ®Google Scholar
• Deng Y, Mo YF, Chen XM, Zhang LZ, Liao CF, Song Y, Xu C. 2016. Effect of Ginkgo biloba extract on the pharmacokinetics and metabolism of clopidogrel in rats. Phytother Res. 30:1886–1892.
   PubMed Web of Science ®Google Scholar
• Dennison TJ, Smith JC, Badhan RK, Mohammed AR. 2017. Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Drug Des Devel Ther. 11:811–826.
   PubMed Web of Science ®Google Scholar
• Dybro AM, Damkier P, Rasmussen TB, Hellfritzsch M. 2016. Statin-associated rhabdomyolysis triggered by drug-drug interaction with itraconazole. BMJ Case Rep. 2016:pii: bcr2016216457.
   Google Scholar
• Eng H, Scialis RJ, Rotter CJ, Lin J, Lazzaro S, Varma MV, Di L, Feng B, West M, Kalgutkar AS. 2016. The antimicrobial agent fusidic acid inhibits organic anion transporting polypeptide-mediated hepatic clearance and may potentiate statin-induced myopathy. Drug Metab Dispos. 44:692–699.
   PubMed Web of Science ®Google Scholar
• Etheridge AS, Black SR, Patel PR, So J, Mathews JM. 2007. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med. 73:731–741.
   PubMed Web of Science ®Google Scholar
• Guan H, Qian D, Ren H, Zhang W, Nie H, Shang E, Duan J. 2014. Interactions of pharmacokinetic profile of different parts from Ginkgo biloba extract in rats. J Ethnopharmacol. 155:758–768.
   PubMed Web of Science ®Google Scholar
• Higgins JW, Ke AB, Zamek-Gliszczynski MJ. 2014. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metab Dispos. 42:1780–1784.
   PubMed Web of Science ®Google Scholar
• Hsiao SH, Chang HJ, Hsieh TH, Kao SM, Yeh PY, Wu TJ. 2016. Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review. J Clin Pharm Ther. 41:575–578.
   PubMed Web of Science ®Google Scholar
• Kadam P, Ashavaid TF, Ponde CK, Rajani RM. 2016. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 41:329–333.
   PubMed Web of Science ®Google Scholar
• Kasabri V, Al-Hallaq EK, Bustanji YK, Abdul-Razzak KK, Abaza IF, Afifi FU. 2017. Antiobesity and antihyperglycaemic effects of Adiantum capillus-veneris extracts: in vitro and in vivo evaluations. Pharm Biol. 55:164–172.
   PubMed Web of Science ®Google Scholar
• Kashihara Y, Ieiri I, Yoshikado T, Kazuya M, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N, et al. 2017. Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of five probes for OATP2B1 and BCRP. J Pharm Sci. 106:2688–2694.
   PubMed Web of Science ®Google Scholar
• Lin CC, Cheng WL, Hsu SH, Chang CM. 2003. The effects of Ginkgo biloba extracts on the memory and motor functions of rats with chronic cerebral insufficiency. Neuropsychobiology. 47:47–51.
   PubMed Web of Science ®Google Scholar
• Liu JE, Ren B, Tang L, Tang QJ, Liu XY, Li X, Bai X, Zhong WP, Meng JX, Lin HM, et al. 2016. The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin. Sci Rep. 6:26544.
   PubMed Web of Science ®Google Scholar
• Liu XP, Luan JJ, Goldring CE. 2009. Comparison of the antioxidant activity amongst Gingko biloba extract and its main components. Zhong Yao Cai. 32:736–740.
   PubMedGoogle Scholar
• Palle S, Neerati P. 2017. Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases. Pharmacol Rep. 69:365–370.
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW, Wang AX, Hou J, Zhu LL, Yang L, et al. 2013. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 56:392–397.
   PubMed Web of Science ®Google Scholar
• Qin CZ, Ren X, Tan ZR, Chen Y, Yin JY, Yu J, Qu J, Zhou HH, Liu ZQ. 2014. A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 28:197–203.
   PubMed Web of Science ®Google Scholar
• Rao Z, Qin H, Wei Y, Zhou Y, Zhang G, Zhang F, Shao Y, Huang J, Wu X. 2014. Development of a dynamic multiple reaction monitoring method for determination of digoxin and six active components of Ginkgo biloba leaf extract in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 959:27–35.
   PubMed Web of Science ®Google Scholar
• Roth L, Rombouts M, Schrijvers DM, Martinet W, De Meyer GR. 2016. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture. Vascul Pharmacol. 80:50–58.
   PubMed Web of Science ®Google Scholar
• Shu N, Hu M, Ling Z, Liu P, Wang F, Xu P, Zhong Z, Sun B, Zhang M, Li F, et al. 2016. The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1. Sci Rep. 6:33072.
   PubMed Web of Science ®Google Scholar
• Sun S, Wang R, Fan J, Zhang G, Zhang H. 2018. Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. Pharm Biol. 56:104–108.
   PubMed Web of Science ®Google Scholar
• Turkanovic J, Ward MB, Gerber JP, Milne RW. 2017. Effect of garlic, Gingko, and St. John’s Wort extracts on the pharmacokinetics of fexofenadine: a mechanistic study. Drug Metab Dispos. 45:569–575.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang H, Sun S, Wang Y, Chai Y, Yuan Y. 2016. Effect of Ginkgo leaf tablets on the pharmacokinetics of amlodipine in rats. Eur J Drug Metab Pharmacokinet. 41:825–833.
   PubMed Web of Science ®Google Scholar
• Wang YC, Hsieh TC, Chou CL, Wu JL, Fang TC. 2016. Risks of adverse events following coprescription of statins and calcium channel blockers: a nationwide population-based study. Medicine (Baltimore). 95:e2487.
   PubMed Web of Science ®Google Scholar
• Wei KK, Zhang LR. 2015. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin. Clin Drug Investig. 35:583–591.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Y, Wang J, Sun K, Tao W, Wang Z, Xiao W, Pan Y, Zhang S, Wang Y. 2017. Systematic investigation of Ginkgo biloba leaves for treating cardio-cerebrovascular diseases in an animal model. ACS Chem Biol. 12:1363–1372.
   PubMed Web of Science ®Google Scholar
• Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatte T, Fuhr U. 2012. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol. 68:553–560.
   PubMed Web of Science ®Google Scholar